Back
Compare AU
Compare HYGG vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Hyperion Global Growth Companies Fund - Active ETF (HYGG) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
HYGG | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 119 | 73 |
Median incremental investment | $993.50 | $736.96 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,260.01 | $2,076.80 |
Average age group | > 35 | > 35 |
Key Summary
HYGG | DRUG | |
|---|---|---|
Strategy | HYGG.AX was created on 2014-06-01 by Hyperion. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to achieve long-term returns above the benchmark, and minimise the risk of permanent capital loss | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Tesla Inc (12.96 %) Alphabet Inc Class A (9.61 %) Meta Platforms Inc Class A (7.48 %) | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Information Technology (40.46 %) Consumer Discretionary (27.08 %) Communication Services (16.69 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | United States (92.29 %) Netherlands (3.76 %) France (2.37 %) | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) |
Management fee | 0.7 % | 0.57 % |
Key Summary
HYGG | DRUG | |
|---|---|---|
Issuer | Hyperion | BetaShares |
Tracking index | MSCI World Index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.7 % | 0.57 % |
Price | $6.43 | $8.80 |
Size | $3.363 billion | $173.548 million |
10Y return | 367.81 % | 82.19 % |
Annual distribution yield (5Y) | 11.49 % | 1.82 % |
Market | ASX | ASX |
First listed date | 21/03/2021 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
HYGG | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 119 | 73 |
Median incremental investment | $993.50 | $736.96 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,260.01 | $2,076.80 |
Average age group | > 35 | > 35 |
Pros and Cons
HYGG | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
HYGG | DRUG |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |